Renata (DHA:RENATA) Stock Based Compensation: BDT0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:RENATA Renata PLC DHA:RENATA
86 GF Score
Price BDT472.70
GF Value BDT817.92
Valuation Significantly Undervalued
! 8 Warning Signs
View Full Analysis

What is Renata Stock Based Compensation?

Renata DHA:RENATA -0.30% 86 Stock Based Compensation is BDT0 Mil as of Mar. 2026. GuruFocus rates DHA:RENATA with a GF Score™ of 86/100 and a GF Value™ of BDT817.92 (Significantly Undervalued). The stock has 8 warning signs investors should review.

Renata's Stock Based Compensation for the three months ended in Mar. 2026 was BDT0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was BDT0 Mil.

Renata Stock Based Compensation Related Terms

Renata Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Renata's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renata Stock Based Compensation Chart

Renata Annual Data
Trend Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Renata Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DHA:RENATA
86GF Score
Renata PLC DHA:RENATA
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Renata Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT0 Mil.

What does a Stock Based Compensation of BDT0 Mil mean?
Renata (DHA:RENATA) has a Stock Based Compensation of BDT0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Renata and its competitors.
Is Renata's Stock Based Compensation too high?
Renata's current Stock Based Compensation is BDT0 Mil. Overall, Renata has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Renata's Stock Based Compensation compare to ZTS and UTHR?
Renata's Stock Based Compensation of BDT0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Renata and its competitors. Renata's current Stock Based Compensation is BDT0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renata stock overvalued right now?
Based on GuruFocus' analysis, Renata (DHA:RENATA) is currently considered Significantly Undervalued. The stock's GF Value™ is BDT817.92, compared to a current price of BDT472.70 — trading 42.2% below its estimated fair value. The current Stock Based Compensation is BDT0 Mil. Renata's overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Renata (DHA:RENATA), the current Stock Based Compensation is BDT0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Renata (DHA:RENATA) Overvalued in 2026?

Based on GuruFocus' analysis, Renata stock appears to be undervalued. The current stock price of BDT472.70 is trading 42.2% below its estimated GF Value™ of BDT817.92. GuruFocus considers Renata to be Significantly Undervalued.

Key valuation signals for DHA:RENATA:

  • Stock Based Compensation: BDT0 Mil
  • GF Value™: BDT817.92 vs. price of BDT472.70 (42.2% below fair value)
  • GF Score™: 86/100 with 8 warning signs

No single metric tells the full story. See the DHA:RENATA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Renata Business Description

Address Plot Number 1, Milk Vita Road, Section-7, GPO Box No. 303, Mirpur, Dhaka, BGD, 1216
Renata PLC is a Bangladesh based pharmaceutical company. It is engaged in the manufacturing, marketing, and distribution of Human Pharmaceuticals, Animal Health Medicines, Nutritionals, and Vaccines. It manufactures various pharmaceutical products including Beconex Zi Syrup, Cabolin Tablet, Flontin Tablet, Ivana Tablet, and others. Some of the animal health products offered by the company are Doxivet Powder, Fevenil Injection, Diadin Bolus, Renamet Tablet, and others. The company operates in Bangladesh and sells its products locally and internationally.
86GF Score

Get the complete analysis for DHA:RENATA

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT472.70
Price
BDT817.92
GF Value